Texas MDL Panel Consolidates Mylan Cases

Law360, New York (August 7, 2009, 1:56 PM EDT) -- The Texas multidistrict litigation panel has consolidated cases alleging that Mylan Pharmaceutical Inc. failed to warn people that its anti-seizure medication causes the development of severe skin disorders.

In an order Wednesday, the panel said it was allowing the transfer and assignment to a pretrial court requested by Mylan because the cases allege the same defect concerning the same drug, Phenytoin, which Mylan markets as Phenytek.

The 10 cases, as well as any tagalong cases, were sent to Judge Jeff Walker of the 96th District Court...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.